You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新天藥業(002873.SZ):持續加大在研發方面的投入 在研項目主要包括中藥創新藥等
格隆匯 12-01 08:53

格隆匯12月1日丨新天藥業(002873.SZ)近期在接待機構投資者調研時表示,公司近幾年持續加大在研發方面的投入,在研項目主要包括中藥創新藥、配方顆粒、經典名方、醫藥級保健品及已上市產品再研究等。目前,配方顆粒的國標轉化進程基本緊跟國家行業發展節奏;其他研發項目也都在按計劃努力抓緊推進中,預計從明年開始,部分項目將陸續提交註冊申請。

另外,公司特別重視上市後臨牀醫學研究,未來研發資源投入也會有序增加。這將不斷豐富公司對上市後產品的臨牀驗證與人用經驗的數據積累,也為產品適應症、劑型等二次開發與再研究提供更強大的數據支持,符合國家對現代中藥臨牀價值導向的基本邏輯。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account